IRVINE, CA / ACCESSWIRE / October 30, 2020 / Terra Tech Corp. (OTCQX:TRTC) ("Terra Tech") or (the "Company") today announced that it will release its Third Quarter 2020 results on Friday, November 6, 2020 after U.S. markets close.

The Company will also host a conference call on Friday, November 6, 2020 at 4:30 PM Eastern Time.

Dial-In Number: 1-857-232-0157
Access Code: 422095

Mike Nahass, CEO of Terra Tech Corp. will be answering shareholder questions at the end of the call. Should you have questions during or prior to the conference call please send an email to TRTC@kcsa.com with TRTC Question in the subject line. Mr. Nahass will answer as many questions as time will allow.

For those unable to participate in the live conference call, a replay will be available at https://www.smallcapvoice.com/trtc/. An archived version of the webcast will also be available on the investor relations section of the company's website.

To be added to the Terra Tech email distribution list, please email TRTC@kcsa.com with TRTC in the subject line.

About Terra Tech
Terra Tech is a holding company with a portfolio of investments focused on cannabis agricultural assets in the THC market and the research, development and commercialization of cannabinoid-based products. Backed by innovative science and best-in-class manufacturing, the company's mission is to deliver top-tier cannabis and cannabinoid-based products with a focus on its core cannabis business.

Cautionary Language Concerning Forward-Looking Statements
Certain statements contained in this communication regarding matters that are not historical facts, are forward-looking statements within the meaning of Section 21E of the Securities and Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, known as the PSLRA. These include statements regarding management's intentions, plans, beliefs, expectations or forecasts for the future, and, therefore, you are cautioned not to place undue reliance on them. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. Terra Tech undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise, except to the extent required by law. We use words such as "anticipates," "believes," "plans," "expects," "projects," "future," "intends," "may," "will," "should," "could," "estimates," "predicts," "potential," "continue," "guidance," and similar expressions to identify these forward-looking statements that are intended to be covered by the safe-harbor provisions of the PSLRA. Such forward-looking statements are based on our expectations and involve risks and uncertainties; consequently, actual results may differ materially from those expressed or implied in the statements due to a number of factors.

New factors emerge from time to time and it is not possible for us to predict all such factors, nor can we assess the impact of each such factor on the business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. These risks, as well as other risks associated with the combination, will be more fully discussed in our reports with the SEC. Additional risks and uncertainties are identified and discussed in the "Risk Factors" section of Terra Tech's Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and other documents filed from time to time with the SEC. Forward-looking statements included in this release are based on information available to Terra Tech as of the date of this release. Terra Tech undertakes no obligation to update such forward-looking statements to reflect events or circumstances after the date of this release.

CONTACT:
Philip Carlson
KCSA Strategic Communications
TRTC@kcsa.com
212-896-1238

SOURCE: Terra Tech Corp.

ReleaseID: 613476

ENGLEWOOD, CO / ACCESSWIRE / October 30, 2020 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's intimate health, today announced that Sharon Collins Presnell, Ph.D. has joined the Viveve board of directors and its audit committee, effective October 28, 2020. The appointment of Dr. Presnell brings the company in compliance with the corporate governance requirements under Listing Rules 5605(b)(1) and 5605(c)(2) of the Nasdaq Stock Market.

"It is with pleasure that I welcome Dr. Presnell to our board, especially during this period of momentum in our stress urinary incontinence clinical development program," said Steve Basta, chairman of the Viveve board of directors. "Sharon's experience spans academic, start-up, and Fortune 500 environments and includes the successful development of both technical and commercial strategies related to cell-based therapies. She brings exceptional research and development experience in cellular pathology and scientific leadership that will contribute greatly as Viveve advances its dual energy technology platform and pivotal PURSUIT trial in stress incontinence."

"We are excited to have Dr. Presnell join the board of directors and recognize the high level of scientific expertise in cellular pathology that she brings to the company. We look forward to working with her to further demonstrate our technology's cellular mechanism of action in the treatment of female stress urinary incontinence," remarked Scott Durbin, Viveve's chief executive officer.

Dr. Sharon Presnell currently serves as President of the Amnion Foundation, a not-for-profit organization ethically addressing birth tissue-derived cells in regenerative medicine and drug development. Concurrently, she is the founder/owner of CytoStrategy and provides life sciences consulting services to companies and organizations throughout the U.S. and E.U. Holding a B.S in cellular biology and Ph.D. in experimental pathology, Dr. Presnell transitioned from a university faculty position to Director of R&D at Becton Dickinson. Her previous executive leadership positions in the biotech industry include the role of President at Samsara Sciences, Inc., a wholly owned subsidiary of Organovo, Inc. where she held positions as Chief Scientific Officer, Chief Technology Officer and Executive Vice President of R&D. Sharon has served continuously as a scientific, technical, and translational reviewer for the NIH for over 20 years. Her specialty is developing strategies for the successful development of nascent technologies, including considerations of science, organizational structure, and economic factors.

About Viveve

Viveve Medical, Inc. is a medical technology company focused on women's intimate health. Viveve is committed to advancing new solutions to improve women's overall well-being and quality of life. The internationally patented Viveve® System incorporates Cryogen-cooled Monopolar Radiofrequency technology to uniformly deliver volumetric heating while gently cooling surface tissue to generate neocollagenesis in a single in-office session. In the United States, the Viveve® System is cleared by the Food and Drug Administration (FDA) for use in general surgical procedures for electrocoagulation and hemostasis. International regulatory approvals and clearances have been received for vaginal laxity and/or improvement in sexual function indications in more than 50 countries.

Viveve continues to advance its clinical development program in SUI. The positive topline results reported from the 3-arm feasibility study and the preclinical study outcomes are intended to support the initiation of the pivotal PURSUIT trial and strengthen its potential to achieve its primary efficacy endpoint. As announced on July 7, 2020, Viveve received FDA approval of its Investigational Device Exemption application to conduct the multicenter, randomized, double-blinded, sham-controlled PURSUIT Trial for improvement of SUI in women.

For more information visit Viveve's website at www.viveve.com.

Safe Harbor Statement

All statements in this press release that are not based on historical fact are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. While management has based any forward-looking statements included in this press release on its current expectations, the information on which such expectations were based may change. These forward-looking statements rely on a number of assumptions concerning future events and are subject to a number of risks, uncertainties, and other factors, many of which are outside of our control, which could cause actual results to materially differ from such statements. Such risks, uncertainties and other factors include, but are not limited to, the fluctuation of global economic conditions, the impact of the novel coronavirus termed COVID-19 on our clinical development and regulatory review and clearances and on the manufacturing, placements and patient utilization of our Viveve Systems, the performance of management and our employees, the outcome of our assessment of strategic alternatives, our ability to obtain financing, our evaluation of strategic alternatives, our ability to obtain approval or clearance for sale of our medical device for all indications sought, competition, general economic conditions and other factors that are detailed in our periodic and current reports available for review at www.sec.gov. Furthermore, we operate in a highly competitive and rapidly changing environment where new and unanticipated risks may arise. Accordingly, investors should not place any reliance on forward-looking statements as a prediction of actual results. We disclaim any intention to, and undertake no obligation to, update or revise forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware, unless required by law.

Viveve is a registered trademark of Viveve, Inc.

Investor Relations contacts:
Amato and Partners, LLC
Investor Relations Counsel
admin@amatoandpartners.com

Media contact:
Bill Berry
Berry & Company Public Relations
(212) 253-8881
bberry@berrypr.com

SOURCE: Viveve Medical, Inc.

ReleaseID: 613458

LITTLETON, CO / ACCESSWIRE / October 30, 2020 / Ur-Energy Inc. (NYSE American:URG)(TSX:URE) (the "Company" or "Ur-Energy") has filed the Company's Form 10-Q for the quarter ended September 30, 2020, with the U.S. Securities and Exchange Commission at www.sec.gov/edgar.shtml and with Canadian securities authorities at www.sedar.com.

Ur-Energy CEO, Jeff Klenda said, "We are pleased that the U.S. Nuclear Fuel Working Group, as well as bipartisan Congressional support, remains focused on securing the future of our industry and our nation. As we await additional positive developments, like the recent amendment and 20-year extension of the Russian Suspension Agreement, we continue our efforts to support the uranium production industry and to safeguard America's national and energy security through the reinvigoration of the front end of our nuclear fuel cycle.

"After making further, market-appropriate adjustments to our Lost Creek operations, we anticipate substantial savings in 2021 and 2022, which are greatly enhanced by the recent agreement to defer principal payments on our State Bond Loan until October 2022. We remain grateful to the State of Wyoming and Sweetwater County for their continuing support. With $5.9 million of cash and approximately 270,000 pounds of finished, ready-to-sell product at the conversion facility, we now have ample runway to support operations into 2022."

Results of Operations

For the three months ended September 30, 2020, 2,503 pounds of U3O8 were captured within the Lost Creek plant and 4,926 pounds of U3O8 were packaged in drums. Our inventory at the converter totaled approximately 268,485 pounds of U3O8 at September 30, 2020.

During the quarter, we took steps to further reduce production operations at Lost Creek and adjust to the continued depressed state of the uranium markets while we await the recommended relief from the Working Group and further positive developments in the uranium markets. The reduced production levels allowed us to make further operating cost reductions at Lost Creek and related support cost reductions at the corporate office in Littleton. The cost reductions include savings from additional reductions in force at both locations as well as other cost containment measures. Together with the further deferral of principal payments on the State Bond Loan, these measures will result in substantial savings to the Company, estimated to exceed $7 million and $4 million in calendar years 2021 and 2022, respectively.

The following tables provide detailed financial information on our sales and cost of sales as they relate to U3O8 pounds. The U3O8 and cost per pound measures included in the following tables do not have a standardized meaning within US GAAP or a defined basis of calculation. These measures are used by management to assess business performance and determine production and pricing strategies. They may also be used by certain investors to evaluate performance. Where applicable, reconciliation of these measures to US GAAP financial statement presentation are included within the respective table.

Sales

 
Unit
 
 
2020 Q3
 
 
2020 Q2
 
 
2020 Q1
 
 
2019 Q4
 
 
2020 YTD
 

U3O8 Sales Reconciliation (1)

Sales per financial statements

 
$000
 
 
$
–
 
 
$
6,934
 
 
$
1,370
 
 
$
10,849
 
 
$
8,304
 

Disposal fees

 
$000
 
 
$
–
 
 
$
(4
)
 
$
–
 
 
$
(1
)
 
$
(4
)

U3O8 sales

 
$000
 
 
$
–
 
 
$
6,930
 
 
$
1,370
 
 
$
10,848
 
 
$
8,300
 

U3O8 pounds sold

 
lb
 
 
 
–
 
 
 
167,000
 
 
 
33,000
 
 
 
180,000
 
 
 
200,000
 

U3O8 price per pound sold

 
$/lb
 
 
$
–
 
 
$
41.50
 
 
$
41.52
 
 
$
60.26
 
 
$
41.50
 

U3O8 Sales by Product

U3O8 Sales

Produced

 
$000
 
 
$
–
 
 
$
–
 
 
$
–
 
 
$
–
 
 
$
–
 

Purchased

 
$000
 
 
$
–
 
 
$
6,930
 
 
$
1,370
 
 
$
10,848
 
 
$
8,300
 

 
$000
 
 
$
–
 
 
$
6,930
 
 
$
1,370
 
 
$
10,848
 
 
$
8,300
 

U3O8 Pounds Sold

Produced

 
lb
 
 
 
–
 
 
 
–
 
 
 
–
 
 
 
–
 
 
 
–
 

Purchased

 
lb
 
 
 
–
 
 
 
167,000
 
 
 
33,000
 
 
 
180,000
 
 
 
200,000
 

 
lb
 
 
 
–
 
 
 
167,000
 
 
 
33,000
 
 
 
180,000
 
 
 
200,000
 

U3O8 Price per Pounds Sold

Produced

 
$/lb
 
 
$
–
 
 
$
–
 
 
$
–
 
 
$
–
 
 
$
–
 

Purchased

 
$/lb
 
 
$
–
 
 
$
41.50
 
 
$
41.52
 
 
$
60.26
 
 
$
41.50
 

 
$/lb
 
 
$
–
 
 
$
41.50
 
 
$
41.52
 
 
$
60.26
 
 
$
41.50
 

Note:

Sales per the financial statements include revenues from disposal fees received at Shirley Basin. The disposal fees do not relate to U3O8 pounds sold and are excluded from the U3O8 sales and U3O8 price per pound sold figures.

There were no sales in the third quarter, and we do not anticipate making any sales in the fourth quarter.

Cost of Sales

 
Unit
 
 
2020 Q3
 
 
2020 Q2
 
 
2020 Q1
 
 
2019 Q4
 
 
2020 YTD
 

U3O8 Cost of Sales Reconciliation (1)

Cost of sales per financial statements

 
$000
 
 
$
1,840
 
 
$
6,517
 
 
$
3,105
 
 
$
6,451
 
 
$
11,462
 

Lower of cost or NRV adjustment

 
$000
 
 
$
(1,840
)
 
$
(2,174
)
 
$
(2,282
)
 
$
(2,074
)
 
$
(6,296
)

U3O8 cost of sales

 
$000
 
 
$
–
 
 
$
4,343
 
 
$
823
 
 
$
4,377
 
 
$
5,166
 

U3O8 pounds sold

 
lb
 
 
 
–
 
 
 
167,000
 
 
 
33,000
 
 
 
180,000
 
 
 
200,000
 

U3O8 cost per pound sold

 
$/lb
 
 
$
–
 
 
$
26.01
 
 
$
24.94
 
 
$
24.31
 
 
$
25.83
 

U3O8 Cost of Sales by Product

U3O8 Cost of Sales

Ad valorem and severance taxes

 
$000
 
 
$
9
 
 
$
6
 
 
$
3
 
 
$
22
 
 
$
18
 

Wellfield cash costs

 
$000
 
 
$
107
 
 
$
154
 
 
$
128
 
 
$
158
 
 
$
389
 

Wellfield non-cash costs

 
$000
 
 
$
557
 
 
$
557
 
 
$
618
 
 
$
611
 
 
$
1,732
 

Plant cash costs

 
$000
 
 
$
807
 
 
$
1,064
 
 
$
910
 
 
$
898
 
 
$
2,781
 

Plant non-cash costs

 
$000
 
 
$
490
 
 
$
490
 
 
$
490
 
 
$
494
 
 
$
1,470
 

Distribution costs

 
$000
 
 
$
4
 
 
$
(3
)
 
$
–
 
 
$
26
 
 
$
1
 

Inventory change

 
$000
 
 
$
(1,974
)
 
$
(2,268
)
 
$
(2,149
)
 
$
(2,209
)
 
$
(6,391
)

Produced

 
$000
 
 
$
–
 
 
$
–
 
 
$
–
 
 
$
–
 
 
$
–
 

Purchased

 
$000
 
 
$
–
 
 
$
4,343
 
 
$
823
 
 
$
4,377
 
 
$
5,166
 

 
$000
 
 
$
–
 
 
$
4,343
 
 
$
823
 
 
$
4,377
 
 
$
5,166
 

U3O8 Pounds Sold

Produced

 
lb
 
 
 
–
 
 
 
–
 
 
 
–
 
 
 
–
 
 
 
–
 

Purchased

 
lb
 
 
 
–
 
 
 
167,000
 
 
 
33,000
 
 
 
180,000
 
 
 
200,000
 

 
lb
 
 
 
–
 
 
 
167,000
 
 
 
33,000
 
 
 
180,000
 
 
 
200,000
 

U3O8 Cost per Pound Sold

Produced

 
$/lb
 
 
$
–
 
 
$
–
 
 
$
–
 
 
$
–
 
 
$
–
 

Purchased

 
$/lb
 
 
$
–
 
 
$
26.01
 
 
$
24.94
 
 
$
24.31
 
 
$
25.83
 

 
$/lb
 
 
$
–
 
 
$
26.01
 
 
$
24.94
 
 
$
24.31
 
 
$
25.83
 

Note:

Cost of sales per the financial statements include lower of cost or net realizable value ("NRV") adjustments. The NRV adjustments do not relate to U3O8 pounds sold and are excluded from the U3O8 cost of sales and U3O8 cost per pound sold figures.

Cost of sales per the financial statements includes ad valorem and severance taxes related to the extraction of uranium, all costs of wellfield and plant operations including the related depreciation and amortization of capitalized assets, reclamation and mineral property costs, plus product distribution costs. These costs are also used to value inventory. The resulting inventoried cost per pound is compared to the NRV of the product, which is based on the estimated sales price of the product, net of any necessary costs to finish the product. Any inventory value in excess of the NRV is charged to cost of sales per the financial statements. These NRV adjustments are excluded from the U3O8 cost of sales and U3O8 cost per pound sold figures because they relate to the pounds of U3O8 in ending inventory and do not relate to the pounds of U3O8 sold during the period.

Continuing Guidance for 2020

Following multiple announcements of industry production suspensions and reductions earlier this year, U3O8 spot prices increased to $33 per pound in June. U3O8 spot prices have decreased to just under $30 per pound since then. While the production cuts may amount to as much as 46 million pounds of primary production on an annualized basis, positive impacts on long-term U3O8 prices have not materialized.

The Working Group report makes several strong recommendations to revitalize domestic uranium mining, most relevant among which is that the U.S. government should make direct purchases of 17 to 19 million total pounds of U3O8 to replenish the American Assured Fuel Supply uranium reserve. Additionally, the report recommends the establishment of a national uranium reserve, which is included in the President's Fiscal Year 2021 Budget Request; during the first year, it is expected that the reserve would directly support the operation of at least two U.S. uranium mines. The budget item is for $150 million per year from FY2021 to FY2030. However, in July the U.S. House Committee on Appropriations decided not to fund the budget item without further information from DOE, for which they directed DOE to submit a plan for the proposed establishment of a uranium reserve within six months of the appropriation bill's enactment.

The amendment and extension of the RSA, completed in early October, continues caps on Russian imports of nuclear fuel to the U.S. for an additional 20 years, through 2040. The amendment reduces the current cap of 20% of demand to an average of 17% of demand over the 20-year period, with reductions starting in 2028 and continuing through 2040. These provisions in the RSA are positive developments in the long term. Notably, Senator Barrasso has introduced legislation to codify the recent extension of the RSA.

Still, no specific action or remedies have resulted from the Working Group's plan at this time and, while the report is strong in its recommendations, there can be no certainty of the final outcome of the Working Group's findings and recommendations, or the timing and impact of any actions taken in response to those findings and recommendations. This includes both the Congressional budget appropriations process and proposed legislation related to the national uranium reserves. The outcome of these continuing processes and its effects on the U.S. uranium market, therefore, remains uncertain.

In addition to the restructuring of the State Bond Loan, we have continued to implement other Company-wide cost-saving measures as we await the recommended relief from the Working Group report and further positive developments in the uranium markets. Recently, we further reduced production operations at Lost Creek to market-appropriate levels. The reduced production levels allowed us to make further operating cost reductions at Lost Creek and related support cost reductions at the corporate office. The cost reductions include savings from additional reductions in force at both locations as well as other cost containment measures. Together with the further deferral of principal payments on the State Bond Loan, these measures will result in substantial savings to the Company, estimated to exceed $7 million and $4 million in calendar years 2021 and 2022, respectively.

With our remaining highly experienced technical and operation staff, we will continue to maintain operational readiness at our fully permitted Lost Creek mine and plant. Ur-Energy is prepared to expand uranium production at Lost Creek to an annualized run rate of one million pounds.

The Lost Creek facility has the constructed and licensed capacity to process up to two million pounds of U3O8 per year and previously reported mineral resources to feed the processing plant for many years to come. A ramp-up of production at Lost Creek will advance further development in the first two mine units, followed by the ten additional mining areas as defined in the Lost Creek Property Preliminary Economic Assessment, as amended. With future development and construction in mind, our current staff members were retained as having the greatest level of experience and adaptability allowing for an easier transition back to full operations. Lost Creek operations can increase to full production rates in as little as six months following a go decision, simply by developing additional header houses within the fully permitted MU2. Development expenses during this six-month ramp up period are estimated to be approximately $14 million and are almost entirely related to MU2 drilling and header house construction costs.

We will continue to closely monitor the uranium market and any actions or remedies resulting from the Working Group's report, DOE's and DOC's efforts, or legislative actions, which may positively impact the uranium production industry. Until such time, we will continue to minimize costs and maximize ‘runway' to maintain current operations and avoid unnecessary dilution while maintaining the operational readiness needed to ramp-up production when called upon.

About Ur-Energy

Ur-Energy is a uranium mining company operating the Lost Creek in-situ recovery uranium facility in south-central Wyoming. We have produced, packaged and shipped more than 2.6 million pounds from Lost Creek since the commencement of operations. Applications are under review by various agencies to incorporate our LC East project area into the Lost Creek permits and to operate at our Shirley Basin Project. Ur-Energy is engaged in uranium mining, recovery and processing activities, including the acquisition, exploration, development and operation of uranium mineral properties in the United States. Shares of Ur‑Energy trade on the NYSE American under the symbol "URG" and on the Toronto Stock Exchange under the symbol "URE." Ur-Energy's corporate office is in Littleton, Colorado; its registered office is in Ottawa, Ontario. Ur-Energy's website is www.ur-energy.com.

FOR FURTHER INFORMATION, PLEASE CONTACT

Jeffrey Klenda, Chair & CEO
866-981-4588
Jeff.Klenda@Ur-Energy.com

Cautionary Note Regarding Forward-Looking Information

This release may contain "forward-looking statements" within the meaning of applicable securities laws regarding events or conditions that may occur in the future (e.g., our ability to maintain safe and compliant, reduced-level production operations at Lost Creek; the ability to readily and cost-effectively ramp-up production operations when market and other conditions warrant; the viability of the additional mining areas at Lost Creek; the impact of ongoing changes in global uranium production and other impacts related to COVID-19; timing and results of implementation of the recommendations from the U.S. Nuclear Fuel Working Group and pending legislation, including the budget appropriations process related to the establishment of the national uranium reserve; the effects on the uranium markets of the extension and amendment of the Russian Suspension Agreement and whether the pending legislation to codify the amendment is enacted; whether cost-savings measures which have been and will be implemented will be sufficient to support our operations and avoid unnecessary dilution to our shareholders) and are based on current expectations that, while considered reasonable by management at this time, inherently involve a number of significant business, economic and competitive risks, uncertainties and contingencies. Factors that could cause actual results to differ materially from any forward-looking statements include, but are not limited to, capital and other costs varying significantly from estimates; failure to establish estimated resources and reserves; the grade and recovery of ore which is mined varying from estimates; production rates, methods and amounts varying from estimates; delays in obtaining or failures to obtain required governmental, environmental or other project approvals; inflation; changes in exchange rates; fluctuations in commodity prices; delays in development and other factors described in the public filings made by the Company at www.sedar.com and www.sec.gov. Readers should not place undue reliance on forward-looking statements. The forward-looking statements contained herein are based on the beliefs, expectations and opinions of management as of the date hereof and Ur-Energy disclaims any intent or obligation to update them or revise them to reflect any change in circumstances or in management's beliefs, expectations or opinions that occur in the future.

SOURCE: Ur-Energy Inc.

ReleaseID: 612752

GulfSlope Provides Update on Corporate Activities and 2021 Operations Update

HOUSTON, TX / ACCESSWIRE / October 30, 2020 / GulfSlope Energy, Inc. (OTCQB:GSPE) ("GulfSlope" or the "Company") today provided an update on recent corporate activities and operational outlook for 2021.

Corporate Update – Response to COVID-19 Pandemic

Global crude oil demand destruction caused by COVID-19 pandemic, together with increased oil production from OPEC and Russia, contributed to a dramatic decrease in the price of oil. Consequently, GulfSlope's management and Board have taken multiple proactive steps during 2020 to preserve liquidity and reduce debt as follows:

Settled the insurance claim related to its Tau prospect, and in accordance with this settlement, GulfSlope received approximately $6.6 million.

Secured agreements which resulted in an overall reduction of approximately $1.1 million in liabilities.

Paid off third-party debt and interest expense of approximately $3.0 million with the expectation that virtually all third-party debt will be retired by the end of 2020.

Initiated filing of loan forgiveness application related to $100,300 loan received from the Paycheck Protection Program.

Accumulated net operating losses of approximately $50 million to offset potential future taxable income.

Operations Update

GulfSlope's Exploration Plan related to the re-drilling of the Company's Tau prospect was approved by the Bureau of Ocean Energy Management on July 16, 2020. The Bureau of Safety and Environmental Enforcement has completed its initial review of the Company's "Application for Permit to Drill," and GulfSlope anticipates receiving final approval once a definitive spud date has been established. The leases associated with the Tau prospect expire in 2022 and 2025, which provides the Company sufficient time to re-drill the Tau prospect.

Tau is a subsalt Miocene prospect located in the Ship Shoal Area, South Addition Blocks 336/351, in approximately 305 feet of water. The Tau No. 2 well is designed to be drilled to 20,000 feet true vertical distance (21,543 feet measured distance) to test multiple intervals that correlate to productive zones in the nearby Mahogany Field, located approximately five miles to the southwest. GulfSlope is the operator with a 25 percent working interest, and Delek GOM Investments LLC, a subsidiary of Delek Group Ltd., owns a 75 percent working interest.

GulfSlope is aggressively pursuing new opportunities to accelerate its business plan, which includes securing additional drilling partners and the acquisition of producing oil and gas assets. GulfSlope is evaluating multiple acquisition opportunities, and the Company believes that a successful acquisition program will complement its legacy exploration program.

"In response to this extraordinarily difficult business environment, we have taken multiple proactive steps at GulfSlope to strengthen the Company and be in a position for success in 2021. We have a relatively clean balance sheet to utilize in the execution of our business strategy," stated John Seitz, Chairman, and CEO of GulfSlope. "As the world economy returns to a more normal demand for hydrocarbons, we are excited about our prospects for 2021, and we continue to believe there is a significant opportunity for our Company."

GulfSlope has received notification from the OTC Markets Group that the Company's closing bid price no longer meets the Standards for Continued Eligibility for OTCQB. GulfSlope has until November 23, 2020, to cure the bid price deficiency. In the event that GulfSlope is unable to cure this deficiency, then the Company anticipates its stock would be subsequently quoted on the OTC Pink Open Market.

About GulfSlope Energy

GulfSlope Energy is an independent oil, and natural gas company focused on offshore U.S. Gulf of Mexico. To learn more, visit the GulfSlope Energy website at www.GulfSlope.com.

Forward-Looking Statements

This press release contains statements that constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. All statements other than statements of historical facts included in this press release are forward-looking statements. The Company can give no assurances that the assumptions upon which the forward-looking statements are based will prove to be correct. Because forward-looking statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by the forward-looking statements. There are a number of risks, uncertainties, and other important factors that could cause actual results to differ materially from the forward-looking statements. Except as otherwise required by the federal securities laws, the Company disclaims any obligations or undertaking to publicly release any updates or revisions to any forward-looking statement contained in this press release to reflect any change in the Company's expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.

CONTACT:
Al Petrie Advisors GulfSlope Energy
Al Petrie John H. Malanga, CFO
Phone: 504-258-9548 Phone: 281-918-4103
Email: al@alpetrie.com Email: john.malanga@gulfslope.com

SOURCE: GulfSlope Energy, Inc.

ReleaseID: 613662

DENVER, CO / ACCESSWIRE / October 30, 2020 / Pure Cycle Corporation (NASDAQ:PCYO) announced it will file its year ended August 31, 2020 Form 10-K before the market opens on November 10, 2020, issue an earnings release with summarized financial information for the three and twelve months ended August 31, 2020, the morning of November 10, 2020, and hold an earnings call on November 10, 2020, to discuss the results. Call details are presented below. For the earnings call, Pure Cycle will post a detailed slide presentation on its website (www.purecyclewater.com), which provides an overview of Pure Cycle and presents summary financial results for the year ended August 31, 2020.

Year Ended August 31, 2020 earnings call information:
When: 4:00PM Eastern (2PM Mountain) on November 10, 2020
Call in number: 1-877-407-8033 (no pass codes required)
International call in number: +1 201-689-8033 (no pass codes required)
Replay available until: Tuesday, November 24, 2020, 4:00PM ET
Replay call in number: 1-877-481-4010, replay pass code: 38547
Event link: https://www.webcaster4.com/Webcast/Page/2247/38547

Company Information

Pure Cycle is a diversified land development and private water utility services company. At our core we are an innovative and vertically integrated wholesale water and wastewater utility service provider that, in addition to developing wholesale water and wastewater utilities, develops a master planned community on land we own and to which we provide water and wastewater services.

Additional information including our recent press releases and SEC filings are available at www.purecyclewater.com, or you may contact our President, Mark W. Harding, or our CFO, Kevin B. McNeill, at 303-292-3456 or at info@purecyclewater.com.

SOURCE: Pure Cycle Corporation

ReleaseID: 613617

De La Fuente Advocates Patient-Centered Care to Improve Prescription Drug Prices, Assisted Living Quality

CORPUS CHRISTI, TX / ACCESSWIRE / October 30, 2020 / Ricardo De La Fuente, the Democratic candidate for U.S. House District 27 in Texas, centers the health care consumer in his campaign for improved care. Price transparency, prescription drug price negotiations, and the latest technology can fulfill America's promise to care for its residents.

The average American spends $1,200 per year on prescription drugs, far surpassing other developed nations. In the 27th District, 31% of residents are uninsured and left exposed to skyrocketing healthcare costs. De La Fuente sees affordable access to healthcare and price transparency as essential to improving the lives of millions of Americans.

De La Fuente knows that the U.S. doesn't have a single healthcare system but competing systems that drive up costs. The COVID-19 outbreak shows that our current system is unequal and inadequate for today's challenges. If elected, he would promote technology and policies that simplify healthcare interactions for millions of patients each year.

Assisted living facilities nationwide represented the number one source of COVID-19 cases early in the outbreak. Staff lacked the resources and guidance to properly help some of our most vulnerable neighbors. De La Fuente believes that protective gear, training, and cutting-edge technology can protect seniors from future outbreaks.

Medicalrecords.com founder Ace Bhattacharjya sees De La Fuente as an emerging leader for the future of American healthcare. "Ricardo understands the need to have low-cost health insurance for all Americans," said Bhattacharjya.

De La Fuente speaks from experience when talking about modernizing the healthcare industry. He has worked with assisted living facilities and tech companies during his business career. As a member of Congress, De La Fuente would use these experiences to build legislation that helps the U.S. achieve its healthcare potential.

CONTACT: De La Fuente Communications
(213) 810-1140
info@ricardoforcongress.com

SOURCE: Ricardo For Congress

ReleaseID: 613643

As an advocate for sustainability, Peter Lowes has connected with local members of his community to help cultivate environmental awareness.

BEND, OR / ACCESSWIRE / October 30, 2020 / As a staunch supporter of environmental sustainability, Bend business owner Peter Lowes is looking to highlight the ongoing global challenges facing our environment today including, the depletion of natural resources, poor waste management, and the overwhelming loss of biodiversity. In an effort to raise awareness, Lowes has partnered with both educators and government officials to establish the non-profit organization, Teaching Environmental Awareness or TEA. While the acronym is a play on his British heritage, tea is also one of the most widely consumed beverages and is associated with a sense of community. The foundation provides scholarships to students who are engaging in educational pursuits in environmental law, studies and sciences.

For more than a decade, Eye On Bend (eyeonbend.com) has been providing a bird's eye view of some of the most visited parts of Bend including the Old Mill District, the Water Park on the Deschutes, the downtown area, and more. While the area has seen exponential growth over the past several decades, the beauty of the natural landscape and picturesque view of the mountainside is what draws individuals to Central Oregon. Currently a percentage of proceeds from EOB sponsors will also benefit TEA and their scholarship program.

Peter is proud to partner with Eye On Bend in an effort to make a positive environmental difference in the community.

For more information on TEA Foundation, please contact founder Peter Lowes at info@teatogether.org.

https://teatogether.org

https://eyeonbend.com

About Peter Lowes

Peter Lowes is a successful businessman and environmental advocate. With a passion for real estate, Peter currently resides in Bend, Oregon, where he runs several businesses. Alongside his professional endeavors, Peter is also always looking for ways to help protect the environment and save the earth's dwindling natural resources.

For more information about Peter Lowes, please visit: https://peter-lowes.com/

Contact Information

Peter Lowes
Email: peter@kbire.com
Website: https://peter-lowes.com/

SOURCE: Peter Lowes 

ReleaseID: 613646